Nomura Asset Management’s Blueprint Medicines BPMC Stock Holding History

Nomura Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,935	Closed	-$1.94M	–	1529
2025 Q1	$1.94M	Buy	21,935 +4,222	+24%	+$412K	0.01%	714
2024 Q4	$1.54M	Sell	17,713 -4,844	-21%	-$444K	﹤0.01%	758
2024 Q3	$2.09M	Buy	22,557 +2,741	+14%	+$272K	0.01%	724
2024 Q2	$2.14M	Sell	19,816 -1,707	-8%	-$171K	0.01%	707
2024 Q1	$2.04M	Buy	21,523 +1,734	+9%	+$149K	0.01%	718
2023 Q4	$1.83M	Hold	19,789	–	–	0.01%	728
2023 Q3	$994K	Hold	19,789	–	–	﹤0.01%	796
2023 Q2	$1.25M	Hold	19,789	–	–	0.01%	781
2023 Q1	$890K	Hold	19,789	–	–	﹤0.01%	809
2022 Q4	$867K	Hold	19,789	–	–	0.01%	819
2022 Q3	$1.3M	Hold	19,789	–	–	0.01%	753
2022 Q2	$1,000K	Sell	19,789 -8,170	-29%	-$479K	0.01%	815
2022 Q1	$1.79M	Sell	27,959 -1,976	-7%	-$142K	0.01%	752
2021 Q4	$3.21M	Buy	29,935 +5,172	+21%	+$541K	0.02%	625
2021 Q3	$2.55M	Sell	24,763 -3,088	-11%	-$288K	0.01%	651
2021 Q2	$2.45M	Hold	27,851	–	–	0.01%	687
2021 Q1	$2.71M	Buy	+27,851	New	+$2.78M	0.02%	617

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nomura Asset Management's BPMC Position: Q2 2025 in Review

Nomura Asset Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 21,935 shares — an estimated $1.94M sold.

Nomura Asset Management first reported a position in BPMC in Q1 2021 and held it in 17 quarters. The position peaked at $3.21M in Q4 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Nomura Asset Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Nomura Asset Management sold 21,935 Blueprint Medicines shares in Q2 2025, an estimated $1.94M.
Nomura Asset Management first reported a position in Blueprint Medicines in Q1 2021 and held it in 17 quarters.
Nomura Asset Management's Blueprint Medicines position peaked at $3.21M in Q4 2021.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Nomura Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.